RecruitingPhase 1NCT06626919

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Sponsor

Arcellx, Inc.

Enrollment

30 participants

Start Date

Apr 30, 2025

Study Type

INTERVENTIONAL

Conditions

Myasthenia Gravis Muscle Weakness Autoimmune Diseases Autoimmune Diseases of the Nervous System Muscular Diseases Autoimmune Neuromuscular Manifestations

Summary

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Standard Lymphodepletion regimen and a biological treatment called anito-cel for people with autoimmune, autoimmune diseases, and other related conditions. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALanito-cel

Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain

DRUGStandard Lymphodepletion regimen

Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion

Locations(13)

UCLA Medical Center

Los Angeles, California, United States

University of California, Irvine

Orange, California, United States

Stanford Hospital

Palo Alto, California, United States

University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare

Tampa, Florida, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

University of Minnesota Delaware Clinical Research Unit

Minneapolis, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

Columbia University Irving Medical Center

New York, New York, United States

Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University (OHSU)

Portland, Oregon, United States

Temple University Hospital

Philadelphia, Pennsylvania, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Houston Methodist Hospital

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06626919

Related Trials

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT069481102 locations

Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults

NCT069981341 location

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT076737442 locations

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

NCT071444621 location